D-0474-2023 Class III Terminated

Recalled by SUN PHARMACEUTICAL INDUSTRIES INC — Princeton, NJ

FDA drug recall D-0474-2023 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on Mar 9, 2023 and is designated Class III. Reason for recall: Failed Content Uniformity Specifications The recall status is terminated (terminated Oct 18, 2023). Affected quantity: 1,920 bottles.

Recall details

Product Type
Drugs
Report Date
Mar 29, 2023
Initiation Date
Mar 9, 2023
Termination Date
Oct 18, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,920 bottles

Product description

Dofetilide Capsules, 500 mcg (0.5 mg), 60-count bottle, Rx only, Manufactured by: Sun Pharmaceutical Industries Limited, Survey No. 259/15, Dadra-396 191, (U.T. of D & NH), India, NDC 47335-0063-86

Reason for recall

Failed Content Uniformity Specifications

Distribution pattern

USA nationwide.

Code information

Lot # DND1541A, Exp 08/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0474-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0474-2023. Report a data issue: hello@regdatalab.com.